INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 263 filers reported holding INTELLIA THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $612,321 | -12.1% | 19,365 | +13.4% | 0.00% | -33.3% |
Q2 2023 | $696,400 | +39.2% | 17,077 | +27.2% | 0.00% | +50.0% |
Q1 2023 | $500,238 | +1.4% | 13,422 | -5.1% | 0.00% | 0.0% |
Q4 2022 | $493,240 | -38.1% | 14,137 | -0.7% | 0.00% | -60.0% |
Q3 2022 | $797,000 | +47.0% | 14,240 | +36.0% | 0.01% | +66.7% |
Q2 2022 | $542,000 | -40.9% | 10,470 | -17.0% | 0.00% | -50.0% |
Q1 2022 | $917,000 | -62.7% | 12,615 | -39.3% | 0.01% | -64.7% |
Q4 2021 | $2,456,000 | +6.8% | 20,770 | +21.1% | 0.02% | -10.5% |
Q3 2021 | $2,300,000 | -4.0% | 17,145 | +15.9% | 0.02% | -13.6% |
Q2 2021 | $2,395,000 | +95.8% | 14,794 | -2.9% | 0.02% | +69.2% |
Q1 2021 | $1,223,000 | +606.9% | 15,243 | +379.6% | 0.01% | +550.0% |
Q4 2020 | $173,000 | +1822.2% | 3,178 | +601.5% | 0.00% | – |
Q3 2020 | $9,000 | +800.0% | 453 | +754.7% | 0.00% | – |
Q2 2020 | $1,000 | -85.7% | 53 | -79.4% | 0.00% | – |
Q3 2018 | $7,000 | -30.0% | 257 | -31.5% | 0.00% | -100.0% |
Q2 2018 | $10,000 | – | 375 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Discovery Value Fund | 572,950 | $19,990,226 | 5.79% |
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $39,952,225 | 5.34% |
MPM BioImpact LLC | 455,238 | $15,883,254 | 4.12% |
ARK Investment Management | 9,420,782 | $328,691,084 | 2.85% |
Atlas Venture Associates IX, LLC | 10,000 | $348,900 | 1.74% |
Ghisallo Capital Management LLC | 250,000 | $8,722,500 | 1.55% |
Nikko Asset Management Americas, Inc. | 2,976,002 | $103,743,430 | 1.49% |
Prosight Management, LP | 72,116 | $2,516,127 | 1.37% |
Rokos Capital Management LLP | 826,063 | $28,391,785 | 1.24% |
Elmwood Wealth Management, Inc. | 67,899 | $2,368,996 | 1.18% |